Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05579470 · ClinicalTrials.gov registry record · NA

Expanding Medication-Assisted Therapies in Central Asia

A NA study of Opioid Use Disorder, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
900
Enrollment target
4
Study locations

NCT05579470: Recruiting NA study of Opioid Use Disorder, sponsored by Yale University.

NCT05579470 is a NA study of Opioid Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 900 participants, below the 4,653-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (81% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05579470, a NA study of Opioid Use Disorder, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
900 participants
Enrollment target
4
Study locations

Study Summary

Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (PWID) and their sexual partners, and scaling up opioid agonist therapies (OAT) in this region is the most cost-effective strategy to prevent new HIV infections, and more effective when combined with antiretroviral therapy (ART). The investigators propose to use the Network for the Improvement of Addiction Treatment (NIATx) implementation strategy to scale-up OAT in three diverse Central Asian countries (Kazakhstan, Kyrgyzstan, Tajikistan) and guided by the Exploration-Planning-Implementation-Sustainment (EPIS) framework. Understanding the trajectories of implementation and scale-up in this context may emerge through creating communities of practice, especially when cohesion and competence evolves, and may guide other healthcare delivery challenges in the region (e.g., HIV, TB); as well as build important regional expertise and understanding implementation trajectories should help support OAT program sustainability.

Primary Outcome

Absolute number of patients on OAT per country

Conditions Studied

Interventions

  • BEHAVIORAL NIATx

Study Locations (4)

Other

  • Columbia University Global Health Research Center of Central Asia - Almaty
  • Den Sooluk Nuru - Bishkek
  • Institute for International Health and Education - Dushanbe

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2023-08-07
Est. Completion 2026-12-31
Phase NA
Yale University

1,492 total trials

What NCT05579470 shows while recruiting

NCT05579470 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, below the 4,653-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which NIATx is the first listed.

NCT05579470 reports a single indexed study location in Other, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05579470 about?

NCT05579470 is a clinical study titled "Expanding Medication-Assisted Therapies in Central Asia". Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (PWID) and their sexual partners, and scaling up opioid agonist therapies (OAT) in this region is the most cost-effective strategy to prevent new HIV infections, and more effe...

What is the current status of trial NCT05579470?

This trial is currently recruiting. It is a NA study. The enrollment target is 900 participants. The study started on 2023-08-07. Estimated completion is 2026-12-31.

What conditions does trial NCT05579470 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT05579470?

The interventions under investigation include: NIATx (BEHAVIORAL).

Who is sponsoring clinical trial NCT05579470?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05579470 being conducted?

This trial has 4 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05579470's enrollment target sits among peer trials

900 21st of 257 higher than 236 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02352116 · 900 participants · NA

    Evaluation of Post-PACU Pain Management in Pediatric Surgery

  • NCT02414347 · 900 participants

    F 18 T807 Tau PET Imaging of Alzheimer's Disease

  • NCT02670408 · 900 participants

    Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

  • NCT02960022 · 900 participants · Phase 2

    A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05579470, the US trial registry maintained by the National Library of Medicine. NCT05579470 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.